Tocilizumab is a humanized antibody against the membrane and soluble receptors for interleukin-6. Tocilizumab is among the disease-modifying antirheumatic drugs (DMARDs) used to treat moderate-to-severe active rheumatoid arthritis (RA) refractory to conventional DMARDs. We report a case of macrophage activation syndrome that complicated acute hepatitis E and started within 24hours after the fourth tocilizumab infusion in a patient with RA.
Keywords: Acute hepatitis E; Macrophage activation syndrome; Rheumatoid arthritis; Tocilizumab.
Copyright © 2015 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.